A detailed history of Bessemer Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 165 shares of RVNC stock, worth $424. This represents 0.0% of its overall portfolio holdings.

Number of Shares
165
Holding current value
$424
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.57 - $2.57 $424 - $424
165 New
165 $1,000
Q3 2020

Nov 12, 2020

SELL
$23.23 - $34.3 $1.47 Million - $2.17 Million
-63,300 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$12.6 - $26.55 $797,580 - $1.68 Million
63,300 New
63,300 $1.55 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.